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Background—The purpose of this study was to assess the long-term value of dobutamine-atropine stress echocardiography
(DSE) for prediction of late cardiac events in patients with proven or suspected coronary artery disease.
Methods and Results—Clinical data and DSE results were analyzed in 1734 consecutive patients undergoing DSE between
1989 and 1997. Seventy-four patients who underwent revascularization within 3 months of DSE and 1 patient lost to
follow-up were excluded; the remaining 1659 (median age, 62 years; range, 14 to 99 years) were followed up for 36
months (range, 6 to 96 months). Wall motion abnormalities at rest and the presence and extent of stress-induced wall
motion abnormalities (ischemia) were scored for each patient. Cardiac events were related to clinical and ECG data and
DSE results. Four hundred twenty-eight cardiac events occurred in 366, documented cardiac death in 108 (total death,
247), nonfatal infarction in 128, and late revascularization in 192 patients. In a multivariable Cox proportional-hazards
model, the ratio of documented cardiac death or (re)infarction was increased in the presence of stress-induced ischemia
(hazard ratio, 3.3; 95% CI, 2.4 to 4.4) and extensive rest wall motion abnormalities (hazard ratio, 1.9; 95% CI, 1.3 to
2.6). The number of ischemic segments was predictive for late cardiac events. A normal DSE carried a relatively good
prognosis, with an annual event rate of cardiac death or infarction of 1.3% over a 5-year period.
Conclusions—In a large group of patients, DSE has an added value for predicting late cardiac events during long-term
follow-up, improving the separation between high- risk and very-low-risk patients. (Circulation. 1999;99:757-762.)
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Dobutamine-atropine stress echocardiography (DSE) iscommonly used to assess the extent, location, and
severity of coronary artery disease (CAD).1 DSE is widely
available and particularly useful in patients who cannot
exercise because of noncardiac disease such as stroke or
peripheral vascular disease or when ECG abnormalities
preclude the diagnosis of ischemia. Several studies have
evaluated the prognostic value of DSE for cardiac events
during vascular surgery,2 after acute myocardial infarction,3
and in patients with severe left ventricular dysfunction.4
However, the long-term prognostic value of DSE in a large
study group for late cardiac events remains ill defined.
Assessment of the long-term prognosis of DSE is important
because the test may not only identify high-risk patients in
whom further interventions are necessary but also select
low-risk patients in whom additional procedures and inten-
sive medical follow-up are not required.
The principal purpose of this study was to assess the
prognostic value and usual clinical parameters for late cardiac
events of DSE in a large group of patients.
Methods
Patient Selection
Between 1989 and 1997, 1734 consecutive patients underwent DSE
at the Thoraxcenter (Rotterdam, the Netherlands). The test was
requested for diagnostic reasons in 707 patients, for preoperative
cardiac risk assessment in 722, or for evaluation of viable myocar-
dium in 305 with left ventricular dysfunction. Follow-up was
successful in 1733 of the 1734 patients. Seventy-four patients who
underwent coronary revascularization within 3 months of the DSE
were excluded from analysis. In these patients, the decision to
revascularize was already made on clinical grounds and coronary
angiography results. DSE was performed as part of a protocol to
evaluate the efficacy of new coronary artery intervention procedures.
Data from the remaining 1659 patients are reported.
Clinical cardiac risk factors, including hypertension, smoking,
hypercholesterolemia, diabetes mellitus, the presence congestive
heart failure, angina pectoris, and a previous myocardial infarction
(history and/or ECG), were recorded at the time of the DSE.
Hypertension was indicated if blood pressure $140/90 mm Hg or if
the patient was treated with antihypertensive medication. Diabetes
mellitus was recorded in patients with a fasting glucose level of
$7.8 mmol/L or in those who required treatment, and hypercholes-
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terolemia was indicated if total cholesterol was $6.4 mmol/L or the
patient was receiving lipid-lowering therapy.
DSE Procedure
DSE was performed as previously described.2 b-Blocker medication
was not discontinued for the study. Off-line assessment of echocar-
diographic images was performed by 2 independent investigators.
From 1989 to 1993, a 14-segment 4-point score was used;5 after
1993, a 16-segment 5-point score was used.6 Ischemic myocardium
was considered to be present in segments exhibiting worsening of
movement during stress, except for akinesia becoming dyskinesia,
which was considered a mechanical phenomenon.7 For each patient,
the number of abnormal segments at rest was scored, a wall motion
score index (total score divided by the number of assessable
segments) was calculated at rest and during peak stress on the basis
of the standard 14- or 16-segment model, and the extent and location
of stress-induced ischemia were noted. The location of ischemia was
noted as either anterior (anterior, lateral, apical, and septal) or
posterior (posterior and inferior). The intraobserver and interob-
server agreements of the interpretation of the echocardiographic
images were 92% and 90%, respectively. Extensive rest wall motion
abnormalities (RWMAs) were considered if the wall motion score at
rest was $1.70, which represents the optimal cutoff value for
prediction of late cardiac death, (re) infarction, and revascularization
assessed by receiver-operating characteristic analysis.
Follow-Up
Follow-up data were obtained in 1997, ranging from 6 to 96 months
after DSE. Events were assessed by physicians who were unaware of
the patients’ former stress test results. The present status was
determined by contacting the patient’s general physician and/or
through review of hospital records. The date of the last interview or
review was used to calculate follow-up time. Evaluated end points
included death, myocardial infarction, and coronary revasculariza-
tion. Deaths were classified as either documented cardiac or other.
Cardiac death was defined by clinical data of acute myocardial
infarction and/or significant cardiac arrhythmias and/or refractory
congestive heart failure, together with ECG and autopsy studies
when available; nonfatal myocardial infarction was defined by
cardiac isoenzyme levels and development of new ECG changes.
Revascularization by coronary angioplasty or bypass surgery .3
months after the original DSE was considered to reflect new or
progressive symptoms. In the case of 2 simultaneous cardiac events,
the worse event was chosen: documented cardiac death was consid-
ered less severe than nonfatal infarction, which was less severe than
coronary revascularization.
Statistical Analysis
Univariable and multivariable Cox proportional-hazards regression
models were used to identify independent predictors of late cardiac
events. The risk of a given variable was expressed by a hazard ratio
(HR) with corresponding 95% CIs. Variables were considered
significant if the null hypothesis of no contribution could be rejected
at P50.05. The probability of the absence of cardiac events was
calculated by the Kaplan-Meier method and compared between
groups by use of the log-rank test. Receiver-operating characteristic
analysis was used to determine the “optimal” cutoff point for
prediction of late events with respect the wall motion score at rest
and the number of ischemic segments. The best cutoff point was
defined as the point with the highest sum of sensitivity and
specificity.8
Results
Demographics
Of 1659 patients, 1172 (71%) were male; the median age was
62 years (range, 15 to 99 years). Other characteristics were
previous myocardial infarction, 705 (42%); typical angina
pectoris, 358 (22%); diabetes mellitus, 137 (8%); hypercho-
lesterolemia, 212 (13%); and hypertension, 485 (29%). Three
hundred fifty-nine (20%) were taking b-blockers.
DSE Results
Heart rate during DSE increased from 73614 to 124621
bpm (P50.0001) and systolic blood pressure from 136624 to
138630 mm Hg (P50.004), whereas diastolic blood pressure
decreased from 77613 to 72616 mm Hg (P50.0001). The
highest dobutamine dose used was 10 mg z kg21 z min21 in 3%
of the patients, 20 mg z kg21 z min21 in 12%, 30 mg z kg21 z
min21 in 35%, and 40 mg z kg21 z min21 in 50%. Atropine was
administered in 354 patients (29%). Patients taking b-blocker
therapy before the test required atropine more frequently (167
of 359, 47%) than those who were not (187 of 1300, 14%;
P,0.05). Side effects requiring termination of the test were
cardiac arrhythmias in 22 patients (1.3%) (ventricular fibril-
lation in 3, sustained ventricular tachycardia in 13, and atrial
fibrillation in 6), symptomatic and severe hypotension (de-
crease in systolic blood pressure .40 mm Hg) in 6 (0.4%),
hypertension (.240/130 mm Hg) in 3 (0.2%), and chills in 4
(0.2%). In addition, a number of side effects occurred in
patients who were able to continue the test: short ventricular
tachycardia (,10 complexes) in 44, atrial fibrillation in 21,
and severe asymptomatic hypotension in 61 (4%). Thus, the
total incidence of severe hypotension was 67 (4.4%). There
were no myocardial infarctions or fatal complications of the
stress test.
New wall motion abnormalities (NWMAs) were observed
in 508 patients (31%), and ECG signs of ischemia were seen
in 558 (34%). There was no relation between stress-induced
ischemia (NWMA) and the occurrence of hypotension or
arrhythmias, yet arrhythmias occurred more frequently in
patients with extensive RWMA (wall motion score at rest
.1.70) (P50.001). The test was inconclusive, without
achievement of target heart rate or ischemia, in 6.3% because
of maximum dose of dobutamine and atropine (6%), cardiac
arrhythmias (0.05%), symptomatic hypotension (0.15%), and
nausea or chills (0.1%). Most patients with insufficient heart
rate increase (69 of 95, 73%) were taking b-blockers. The
Kaplan-Meier curves for cardiac death or infarction during
follow-up by results of DSE (with or without NWMA and/or
RWMA). Each plot represents cumulative percentage of patients
remaining event free. A significant difference exists in event-free
survival between patients with NWMAs and RWMAs and those
with normal DSE. MI indicates myocardial infarction.
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cardiac event rate in these patients was not different from the
event rate in patients with a complete DSE.
Follow-Up Results
Of the 74 patients who were referred for coronary revascu-
larization within 3 months of DSE, 49 had stress-induced
myocardial ischemia. None of these patients sustained a
myocardial infarction before revascularization. Death was
assessed in 247 of 1659 patients. Cardiac events occurred in
366 patients: documented cardiac death in 108, nonfatal
myocardial infarction in 128, and late coronary revascular-
ization in 192. Nonfatal stroke occurred in 28 patients.
Predictive Value of Clinical Data and DSE Results
Death occurred in 14% during the 5-year follow-up in
patients with a normal test versus 30% in patients with both
NWMAs and RWMAs (P50.0001) (the Figure). A univari-
able Cox model was used to identify the predictive value for
cardiac events for all clinical data and stress test results. The
significant results for cardiac death, cardiac death or (re)in-
farction, coronary revascularization, and all cardiac event are
presented in Table 1. The strongest univariable predictor was
NWMA. In patients with “limited” ischemia (1 segment), the
HR was 2.9 (range, 1.3 to 3.0), which increased to 4.0 (range,
2.6 to 5.2) (P50.001) if $2 ischemic segments were present.
There was no further increase in HR if .2 segments showed
ischemia. No relation was observed between the location of
ischemic segments (anterior versus inferior) and subsequent
cardiac death or infarction.
In a stepwise logistic regression model, NWMA was the
strongest predictor of cardiac death, infarction, and late
coronary revascularization (Table 2).
To evaluate the additional prognostic value of specific
clinical characteristics and extensive RWMA in patients with
NWMA for the predictive value of cardiac death or infarc-
tion, an interaction analysis was performed (Table 3). In all
patients, induction of NWMA increased the risk for cardiac
death and (re)infarction 2.4-fold. In patients with extensive
RWMA or a left bundle-branch block (LBBB), the incremen-
TABLE 1. Univariable Predictive Value of Clinical Risk Factors for CAD and Stress Results for
Late Cardiac Events
HR (95% CI)
Cardiac
Death
Cardiac
Death/MI Revascularization
Cardiac
Death/MI/Revas-
cularization
NWMA 3.6 (2.4–5.3) 3.6 (2.7–4.9) 4.1 (3.0–5.4) 3.4 (2.8–4.1)
Extensive RWMA 4.5 (3.0–6.6) 2.5 (1.9–3.5) 1.9 (1.5–2.5) 2.3 (1.9–2.7)
ST-segment changes during DSE 2.2 (1.5–3.2) 2.2 (1.6–2.9) 2.0 (1.5–2.7) 2.1 (1.7–2.6)
ECG-detected LBBB 3.6 (2.0–6.6) 3.1 (1.9–5.0) 1.0 (0.5–2.1) 2.3 (1.5–3.2)
Previous MI 2.9 (1.4–3.1) 1.9 (1.4–2.5) 2.5 (1.9–3.4) 2.5 (2.0–3.0)
Diabetes mellitus 1.4 (0.7–2.8) 1.9 (1.2–3.1) 1.2 (0.7–2.0) 1.6 (1.2–2.3)
Angina 1.2 (0.8–1.9) 1.5 (1.1–2.1) 3.6 (2.7–4.8) 2.4 (2.0–2.9)
Age (per year) 1.02 (1.00–1.04) 1.00 (0.99–1.01) 0.99 (0.98–1.00) 0.99 (0.99–1.00)
Age .70 y 1.3 (0.9–2.0) 1.0 (0.7–1.4) 0.5 (0.3–0.8) 0.7 (0.5–0.9)
Hypertension 0.9 (0.6–1.4) 1.0 (0.7–1.4) 1.5 (1.1–2.0) 1.3 (1.0–1.7)
Hypercholesterolemia 0.7 (0.3–1.9) 2.0 (1.1–3.5) 3.8 (2.6–5.6) 4.7 (3.4–6.6)
MI indicates myocardial infarction; Extensive RWMA, wall motion score at rest .1.70. See Methods for definition
of hypertension and hypercholesterolemia.
TABLE 2. Multivariable Predictive Value of Clinical Risk Factors for CAD and
Stress Results for Late Cardiac Events
HR (95% CI)
Cardiac
Death
Cardiac
Death/MI Revascularization
Cardiac
Death/MI/Revas-
cularization
NWMA 3.1 (2.0–4.6) 3.3 (2.4–4.4) 3.3 (2.4–4.5) 3.5 (2.8–4.3)
Extensive RWMA 3.9 (2.6–5.8) 1.9 (1.3–2.6) NS 1.7 (1.4–1.8)
ECG-detected LBBB NS 2.2 (1.4–3.5) NS 1.7 (1.2–2.6)
Diabetes mellitus NS 1.7 (1.0–2.7) NS NS
Angina NS NS 2.4 (1.7–3.2) 1.7 (1.4–2.0)
Age (per year) 1.04 (1.02–1.06) NS NS NS
Hypercholesterolemia NS NS 4.0 (2.7–5.8) 3.0 (2.2–4.1)
Abbreviations and explanations as in Table 1.
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tal value of NWMA was less (1.8 and 2.0, respectively). The
cardiac event rate in patients with hypotension or hyperten-
sion during DSE was not significantly different. The annual
event rate of cardiac death or myocardial infarction was 1.2%
over a 5-year period in 641 patients with a normal DSE (no
RWMA and no NWMA): 5.4% in patients with NWMA and
6.8% in patients with both NWMA and RWMA (the Figure).
Discussion
As shown in previous studies,4,9–11 parameters representing
impaired left ventricular function (extensive RWMA) and
parameters representing the presence or extent of CAD
(NWMA, angina, and a previous infarction) or a high
likelihood of CAD (diabetes mellitus and old age) were
related to cardiac death, (re)infarction, and coronary revas-
cularization at long-term follow-up. This is the first study
using DSE to confirm these results in a large study population
with nearly complete long-term follow-up. The rate of cardiac
death or myocardial infarction in patients with NWMA or
extensive RWMA increased 3.6- and 2.5-fold, respectively.
In patients with extensive RWMA or an LBBB, induction of
NWMA during DSE increased the frequency of cardiac death
or (re)infarction during a 5-year period from 12% to 31% and
from 16% to 44%, respectively (Table 3). The incremental
value of NWMA in these subgroups of patients was less
compared with the entire population. This may be related to
the high pretest likelihood of underlying CAD in both groups
or to the difficulty in assessing NWMA in these patients. The
absence of NWMA, even in patients with b-blocker therapy
and diabetes mellitus, carried a good prognosis, with an
annual rate of any cardiac event of 1.3% (cardiac death,
infraction, or revascularization). Hypotension or hypertension
during DSE did not alter its prognostic value.
In contrast to previous post–myocardial infarction studies, the
predictive value for cardiac death of impaired left ventricular
function in this study was less than markers of ischemia,12
although the difference was not significant. This may be related
to patient selection and study procedures. In most postinfarction
series, patients with signs of ischemia underwent PTCA or
CABG to reduce myocardial ischemia. In contrast, many pa-
tients were enrolled for evaluation before vascular surgery
(42%), whereas few of these patients did undergo PTCA or
CABG. Furthermore, 74 patients (4%) who underwent early
coronary revascularization were excluded from analysis.
Prognostic Value of Noninvasive Stress Testing: A
Comparison Between Stress Echo and Myocardial
Perfusion Imaging
In most comparative studies, stress echocardiography is less
sensitive for the detection of myocardial ischemia but more
specific than perfusion scintigraphy.13 Therefore, DSE may
have an advantage for short-term risk assessment, such as
TABLE 3. Study Results
Presenting Feature
No. of Patients Cardiac Death or MI, n (%) Likelihood Ratio
All
No
NWMA NWMA All No NWMA NWMA
No
NWMA NWMA
b-Blocker use
No 1300 901 399 163 (12.5) 62 (6.9) 101 (25.3) 0.52 2.4
Yes 359 250 109 34 (9.5) 12 (4.8) 22 (20.2) 0.48 2.4
LBBB on ECG
No 1583 1107 476 176 (11.1) 67 (6.1) 109 (22.9) 0.52 2.4
Yes 76 44 32 21 (27.6) 7 (15.9) 14 (43.8) 0.50 2.0
Previous MI
No 954 741 213 79 (8.3) 33 (4.5) 46 (21.6) 0.52 3.1
Yes 705 410 295 118 (16.7) 41 (10.0) 77 (26.1) 0.55 1.8
Rest wall motion score
,1.7 1350 976 374 135 (10.0) 53 (5.4) 82 (21.9) 0.51 2.5
$1.7 309 175 134 62 (20.1) 21 (12.0) 41 (30.6) 0.54 1.8
Diabetes mellitus
No 1522 1061 461 175 (11.5) 67 (6.3) 108 (23.4) 0.52 2.4
Yes 137 90 47 22 (16.1) 7 (7.8) 15 (31.9) 0.44 2.4
Sex
Male 1172 773 399 156 (13.3) 54 (7.0) 102 (25.6) 0.49 2.2
Female 486 377 109 41 (8.4) 20 (5.3) 21 (19.3) 0.61 2.6
Age, y
,70 1207 802 405 149 (12.3) 53 (6.6) 96 (23.7) 0.50 2.2
$70 452 349 103 48 (10.6) 21 (6.0) 27 (26.2) 0.54 3.0
All patients 1659 1151 508 197 (11.9) 74 (6.4) 123 (24.2) 0.51 2.4
Abbreviations as in Table 1.
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preoperative cardiac risk stratification, because more severe
CAD, which is related to perioperative cardiac events, will be
detected and treated with a reduced rate of false-positive
results compared with myocardial perfusion scintigraphy.2
However, mild CAD missed by DSE may have a negative
impact on the long-term prognostic value of a normal DSE.
Previous studies by Krivokapich et al14 with exercise stress
echo and Sciari et al3 and Poldermans et al15 with DSE
reported an average high annual incidence of cardiac death or
infarction of 6.6% to 8.5% in patients with proven or
suspected CAD without stress-induced ischemia. The recent
study of Steinberg et al16 showed a similar frequency of
nonfatal infarction in patients with and without ischemia
during DSE (4.8% versus 3.8%) during a 5-year follow-up in
a group of 120 patients. This seems to be in contrast to the
results with perfusion scintigraphy; the annual event rate of
cardiac death or infarction in patients with a “normal”
perfusion scintigraphy was ,1% (range, 0% to 2.2%) in 3573
patients with a mean follow-up of 28 months,10 and a positive
perfusion scintigraphy increased the annual risk 6- to 12-fold.
It should be appreciated, however, that this analysis was
restricted to patients without perfusion abnormalities at rest
and during stress. If similar patients were studied with DSE
(normal function at rest and during stress), the annual event
rate of cardiac death or infarction was only 1.3% during a
mean follow-up of 36 months (the Figure). The annual
cardiac event rate increased to 6% in patients with NWMA
and to 8% in patients with RWMA and NWMA. This
suggests that the predictive value of both noninvasive tests
(DSE and perfusion scintigraphy) are, in fact, similar. A
recent study17 comparing DSE and 99mTc sestamibi SPECT in
a subgroup of our study population (n5220) showed a
comparable predictive value for both imaging modalities with
the use of dobutamine stress.
Both imaging modalities provide similar incremental prog-
nostic information. The choice of technique should be made
on the basis of availability, local experience, skill, and cost.
Perfusion imaging may be preferred in patients with poor
echographic image quality.
Regional DSE Ischemia
Previous studies with perfusion scintigraphy stressed the
importance of the location and extent of ischemia.10 In
particular, ischemia in the territory of the left anterior
descending artery was related to late cardiac events. In this
study, comparison of anterior (anterior, septal, lateral, and
apex) with posterior (inferior and posterior) induced ischemia
showed no difference in late cardiac events. Furthermore, the
extent of ischemia during DSE was only weakly related to
late cardiac death or infarction. Ischemia in only 1 segment
had a lower risk than in 2 ischemic segments (HR, 2.9 versus
4.0; P50.001) for late cardiac events, but additional ischemic
segments did not increase the annual rate. This may be related
to the higher specificity of DSE for severe CAD compared
with perfusion scintigraphy.
Feasibility and Safety of DSE
DSE has a high feasibility in patients with adequate echocar-
diographic images. The test was inconclusive in only 6.3% of
all patients. This was due mostly to insufficient heart rate
increase despite the use of atropine and dobutamine. Most of
these patients were taking b-blockers. The test might be
repeated after cessation of b-blockers, although a normal test
without “target heart rate” achievement will probably rule out
severe CAD.1
As in previous studies,18 the most frequent side effects
were severe hypotension (4.4%) and cardiac arrhythmias
(5%). Both side effects were not related to the induction of
ischemia. Hypotension was usually well tolerated, did not
interfere with the test, and did not influence the prognostic
value of DSE. Cardiac arrhythmias were more frequent in
patients with extensive RWMA but were not related to
ischemia or the addition of atropine and were mostly
self-limiting.
Study Limitations
The present data apply only to patients with adequate echo-
cardiographic images in whom all myocardial segments were
visible. Our results, obtained in a single center with a high
volume of DSE, and other echo studies do not necessarily
apply to other centers.19 However, major improvements are
expected in echo quality with the introduction in the clinical
area of second harmonic imaging and contrast
echocardiography.20
Conclusions
The risk of future cardiac events can be assessed by DSE,
distinguishing subgroups of patient with high (.30% in 5
years), median (12% in 5 years), and low (8% in 5 years) risk.
In particular, patients with normal results during DSE have a
good prognosis.
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